Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: AF who wrote (95001)	4/27/2000 5:49:00 PM
From: Jenna	Respond to of 120523

CYTC.. nice close looks good going into tormorrow. Cytyc Corporation Doubles Sequential EPS to $0.14 Thinprep(r) Pap Test(TM) Accelerates to 25 Percent of U.S. Pap Tests BOXBOROUGH, Mass., April 27 /PRNewswire/ -- Cytyc Corporation (Nasdaq: CYTC - news) today announced operating and financial results for the first quarter ended March 31, 2000. The Company reported revenues of $28.8 million for the first quarter, a 16 percent increase over the previous quarter and a 78 percent increase over the $16.2 million reported in the first period last year. Net income for the first quarter of 2000 was $5.6 million, nearly double the $2.9 million reported in the fourth quarter of 1999 and eight times the $657,000 reported in the corresponding first quarter of 1999. Diluted earnings per share grew to $0.14 for the first quarter of 2000 compared to $0.07 reported in the preceding quarter and $0.02 reported in last year's first quarter. Patrick J. Sullivan, Cytyc's president and chief executive officer, indicated that use of the ThinPrep(r) Pap Test(TM) increased from 19 percent at the end of 1999 to 25 percent in the first quarter of 2000. ``One of every four Pap tests in the United States is now a ThinPrep Pap Test, compared to one in ten just a year ago,'' said Mr. Sullivan. ``During the quarter, we announced long-term agreements with six of the largest laboratories in the U.S. In addition, we maintained margins that reflect the superiority of the ThinPrep Pap Test.''